EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lakefront Biotherapeutics NV (LKFT) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Lakefront Biotherapeutics NV $92.16, price $30.72, upside +200.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US

LB Lakefront Biotherapeutics NV logo Thin data Sep 24, 2026

Lakefront Biotherapeutics NV

LKFT · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $92.16 · Strongly undervalued (+200%)
✓Quality 70/100
!Expensive Growth (revenue 3y +66.4 %/yr)
✓Highly profitable · 46.8% net margin (TTM)
!negative free cash flow
✓Ranks above peers (9/10)
✓Wide moat 72/100
!Evidence only low, so the estimate is less certain
Watch Lakefront Biotherapeutics NV for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$73.50 $22.69 Fair Value $92.16 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $22.69 – $73.50 · fair‑value band $66.70 – $118.34 · the $30.72 price screens below the $92.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Lakefront Biotherapeutics in your weekly email

Every Wednesday you see whether Lakefront Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

Show more

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Stock analysis

Lakefront Biotherapeutics NV (LKFT) currently trades at $30.72, while our model-based Fair Value estimate is $92.16, implying the stock looks roughly 66.7% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $226.37 per share, and 15 of the 15 models we run sit above the $30.72 price.

Bear case: the Asset-Based group reads lowest at $32.92, and 0 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: $66.70 (bear) to $118.34 (bull), the price of $30.72 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lakefront Biotherapeutics NV reported revenue of €1.1B in FY2025 versus €241M in FY2022, a compound +66.4%/yr. Reported net income was €321M in FY2025.

Key figures

Market cap $2.0B · P/E ratio 3.6 · P/S ratio 1.03 · EPS (TTM) $8.60 · Net margin 28.9% · Return on equity 16.3% · Return on assets (EBIT) 1.3% · Operating margin −983%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 18% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 200%, LKFT screens cheaper than that median.

Fair Value models

Bear $66.70 Fair Value $92.16 Bull $118.34
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($6.29 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $56.15 $63.62 $69.85 70
Residual Income $40.50 $43.89 $52.65 66
ROIC Compounder $63.35 $84.12 $100.93 66
All 15 models by family
DCF Models
Owner Earnings $71.94 $147.67 $288.18 64
Earnings-Based
Graham-Dodd $33.13 $231.06 $324.25 59
Lynch FV $119.37 $170.53 $221.69 57
PEG = 1.0 $119.37 $170.53 $221.69 53
EPV $56.15 $63.62 $69.85 70
Multiples
P/E Multiple $80.39 $107.19 $133.99 63
P/S Multiple $44.33 $59.11 $73.89 58
P/B Multiple $62.12 $82.83 $103.54 55
EV/EBIT $98.40 $130.76 $163.11 63
EV/EBITDA $90.18 $119.80 $149.41 64
EV/Revenue $36.80 $52.00 $67.20 51
Asset-Based
NCAV (Graham) $24.57 $32.92 $49.13 51
Economic Profit
Residual Income $40.50 $43.89 $52.65 66
ROIC Compounder $63.35 $84.12 $100.93 66
Growth Earnings
Growth-Adj P/E $158.46 $226.37 $294.28 63

Open the full fair value analysis →

Notify me when LKFT reaches fair value

Put LKFT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 62 · Market factors (momentum, volatility) 49

Profitability 56
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 84
Calm price path (market factor)
Momentum 35
Price trend over the last 3–12 months (market factor)
52W Momentum 31
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+303.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+66.4%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+22.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.6%
Dividend (yield on the price)0.0%

Watch LKFT, get fair value alerts →

Compare Lakefront Biotherapeutics NV with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +200% · Top 25%
Profitability
Return on equity (TTM) 16% · Top 25%
Return on assets 11% · Top 25%
Net margin (TTM) 47% · Top 25%
Growth and dividend
Revenue growth −91% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 3.6× · Cheapest 25%
P/B 0.63× · Cheaper than median
P/S (TTM) 1.94× · Cheaper than median
EV/EBITDA 2.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)65 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BeOne Medicines AG ONC $368.08 $280.94 −24%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lakefront Biotherapeutics NV · Fair Value
$92.16 +67%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lakefront Biotherapeutics NV Fair Value". https://www.fairvalue-calculator.com/stock/LKFT

Frequently asked questions

Is Lakefront Biotherapeutics NV (LKFT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $92.16 versus a price of $30.72, about +200% upside (undervalued).
What is the fair value of LKFT?
Our model-based fair value for Lakefront Biotherapeutics NV is $92.16 (as of Sep 24, 2026), built from audited fundamentals. The current price: $30.72.
What is the quality score of LKFT?
Lakefront Biotherapeutics NV has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lakefront Biotherapeutics NV (LKFT)?
Our model-based price target is the fair value of $92.16 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario $66.70, optimistic scenario $118.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Lakefront Biotherapeutics NV stock forecast for 2026?
Our models put fair value at $92.16, about +200% upside versus a price of $30.72 (undervalued). Cautious scenario $66.70, optimistic scenario $118.34. The calculation is refreshed regularly with new filings.
What is the revenue of Lakefront Biotherapeutics NV (LKFT)?
Lakefront Biotherapeutics NV reported trailing-twelve-month revenue of about $1.0B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Lakefront Biotherapeutics NV (LKFT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lakefront Biotherapeutics NV it is $92.16 per share (as of Sep 24, 2026), against a price of $30.72. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Lakefront Biotherapeutics NV stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LKFT trades below its calculated fair value: price $30.72, fair value $92.16, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LKFT?
No. The price is what the market pays today ($30.72); the fair value is what the company's own numbers justify ($92.16). For Lakefront Biotherapeutics NV the two are $61.44 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lakefront Biotherapeutics NV worth?
The market values Lakefront Biotherapeutics NV at about $2.0B (market capitalisation, as of Sep 24, 2026). Per share that is $30.72; our models calculate a fair value of $92.16 per share.
What do the bullish and bearish scenarios say about LKFT?
Our models span a range for Lakefront Biotherapeutics NV: cautious scenario $66.70, base $92.16, optimistic $118.34 per share (as of Sep 24, 2026, price $30.72). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LKFT?
Lakefront Biotherapeutics NV trades at a price-to-earnings ratio of 3.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $92.16 is built from several models across several years. Other multiples: P/B 0.6, P/S 1.9, EV/EBITDA 2.9.
How solid is the balance sheet of Lakefront Biotherapeutics NV (LKFT)?
Balance-sheet figures for Lakefront Biotherapeutics NV (as of Sep 24, 2026): return on equity 16.3%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is LKFT from its 52-week high?
Lakefront Biotherapeutics NV trades at $30.72, about 18% below its 52-week high of $37.62 and 18% above the low of $26.08 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $92.16 is for.
Which stocks are comparable to Lakefront Biotherapeutics NV?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lakefront Biotherapeutics NV stock attractive at the current price?
The data as of Sep 24, 2026: price $30.72, calculated fair value $92.16 (+200%), Quality Score 70/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LKFT calculated?
We run Lakefront Biotherapeutics NV through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $92.16, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Lakefront Biotherapeutics NV currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lakefront Biotherapeutics NV (LKFT)?
The closing price on Sep 23, 2026 was $30.72. Our model-based fair value is $92.16, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lakefront Biotherapeutics NV right now?
The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($66.70). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Lakefront Biotherapeutics NV

How large is the market capitalisation of Lakefront Biotherapeutics NV (LKFT)?
The market capitalisation of Lakefront Biotherapeutics NV is $2.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lakefront Biotherapeutics NV (LKFT)?
The price-to-sales ratio of Lakefront Biotherapeutics NV is 1.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lakefront Biotherapeutics NV (LKFT)?
Earnings per share at Lakefront Biotherapeutics NV are $8.60 (price ÷ EPS = P/E 3.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lakefront Biotherapeutics NV (LKFT)?
The net margin of Lakefront Biotherapeutics NV is 28.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lakefront Biotherapeutics NV (LKFT)?
The return on equity (ROE) of Lakefront Biotherapeutics NV is 16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lakefront Biotherapeutics NV (LKFT)?
On an EBIT basis the return on assets of Lakefront Biotherapeutics NV is 1.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lakefront Biotherapeutics NV (LKFT)?
The operating margin of Lakefront Biotherapeutics NV is −983% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lakefront Biotherapeutics NV (LKFT)?
Revenue at Lakefront Biotherapeutics NV is growing −91.4% versus a year earlier (3y avg +66.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Lakefront Biotherapeutics NV (LKFT) generate?
The free cash flow of Lakefront Biotherapeutics NV is −$271M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lakefront Biotherapeutics NV (LKFT) hold?
Lakefront Biotherapeutics NV holds more cash than debt, $81.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lakefront Biotherapeutics NV in the live analysis

One click puts Lakefront Biotherapeutics NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.